BackAerovate Therapeutics Overview

Aerovate Therapeutics Net Tangible Assets

Aerovate Therapeutics's net tangible assets is $300M.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$296.46M
295.04% YoYΔ $221.42M vs prior year quarter

Peer average

Loading

Aerovate Therapeutics Net Tangible Assets History

Loading

Aerovate Therapeutics vs. peers: Net Tangible Assets Comparison

Loading

Aerovate Therapeutics Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Aerovate Therapeutics (AVTE) FAQ

As of the most recent data (March 2026), AVTE shows a net tangible assets of $300M. That compares with $75M in the prior-year period — up 295.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AVTE's net tangible assets is now $300M (was $75M) — a 295.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Aerovate Therapeutics is outperforming or lagging.

Tracking AVTE's net tangible assets over time shows whether Aerovate Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $300M That compares with $75M in the prior-year period — up 295.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net tangible assets page, Stockcircle has Aerovate Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $300M) with ownership activity and broader fundamentals.

Aerovate Therapeutics's net tangible assets is $300M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.